MetaCap

Dermata Therapeutics (DRMA) vs GRI Bio (GRI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Dermata Therapeutics is the larger company by market cap ($2.5 million vs $2.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DRMA-54.51%GRI-39.46%
+5%-26%-57%
Oct 7, 20261 yearNov 20, 2026
DRMA-50.05%GRI-35.63%
+11%-21%-53%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DRMA versus GRI key metrics
MetricDRMAGRI
Share price$0.5095$1.12
Market cap$2.51M$2.45M
1-day change-4.23%0.00%
P/E ratio (TTM)—0.05
EPS (TTM)$-3.28$20.57
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-7.56M$-11.96M
52-week high$4.66$64.12
52-week low$0.50$1.09
Distance from 52-week high-89.07%-98.25%
Analyst consensusnonenone
Avg. price target upside+685.08%+1551.79%
Average volume2.78M218.31K
Shares outstanding4.93M2.19M
Employees93
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Dermata Therapeutics

DRMA stock →

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

About GRI Bio

GRI stock →

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

DRMA vs GRI FAQ

Which is bigger, Dermata Therapeutics or GRI Bio?

Dermata Therapeutics (DRMA) is larger, with a market capitalization of $2.51M compared with $2.45M for GRI Bio (GRI).

Are Dermata Therapeutics and GRI Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons